RTP Mobile Logo
Current Controversies, Recent Developments and Emerging Strategies in the Management of Breast Cancer: A Clinical Investigator Think Tank
Released May 2012

Video excerpts from a clinical investigator Think Tank held on March 2, 2012. Featuring perspectives from Drs Ana Maria Gonzalez-Angulo, William J Gradishar, Daniel F Hayes, Ian E Krop, Hannah M Linden, Eleftherios P Mamounas, Kathy D Miller and Charles L Vogel. (Video Program)

CE Disclosures and Faculty Information


    This activity is intended for medical oncologists and other healthcare providers involved in the treatment of breast cancer.


    Breast cancer is one of the most rapidly evolving fields in medical oncology. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — clinicians must be well informed of these advances. To bridge the gap between research and practice, this program features leading oncology investigators debating the merits, applications and limitations of emerging data sets. By providing access to the latest research developments and expert perspectives, this CME program assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.


    • Determine the utility of genomic assays in counseling patients with ductal carcinoma in situ or ER-positive early breast cancer about their risk of recurrence and the potential benefits of radiation therapy or adjuvant chemotherapy, respectively.
    • Develop evidence-based treatment approaches for patients diagnosed with HER2-positive breast cancer in the neoadjuvant, adjuvant and metastatic settings.
    • Evaluate the unique mechanisms of action and emerging clinical trial data with novel anti-HER2 agents under investigation in breast cancer.
    • Formulate individualized approaches to later-line therapy for patients with HER2-negative metastatic breast cancer.
    • Recall emerging data on the role of mTOR inhibition in reversing resistance to endocrine therapy in metastatic breast cancer in preparation for the potential availability of this treatment approach.
    • For patients with advanced BRCA mutation-associated or triple-negative breast cancer, discuss the clinical activity and safety of PARP inhibitors, alone or with chemotherapy, and provide guidance about available ongoing clinical trials.
    • Define the current role of bone-targeted therapy in the management of early breast cancer.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Ana Maria Gonzalez-Angulo, MD, MSc
    Associate Professor
    Department of Breast Medical Oncology
    Department of Systems Biology
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Bayer HealthCare Pharmaceuticals; Paid Research: Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation; PI on Trial: Genomic Health Inc.

    William J Gradishar, MD
    Betsy Bramsen Professor of Breast Oncology
    Professor of Medicine
    Director, Maggie Daley Center for Women’s Cancer Care
    Robert H Lurie Comprehensive Cancer Center
    Northwestern University Feinberg School of Medicine
    Chicago, Illinois

    No real or apparent conflicts of interest to report.

    Daniel F Hayes, MD
    Clinical Director, Breast Oncology Program
    Stuart B Padnos Professor in Breast Cancer Research
    University of Michigan Comprehensive Cancer Center
    Professor of Internal Medicine
    University of Michigan School of Medicine
    Ann Arbor, Michigan

    Paid Research: Novartis Pharmaceuticals Corporation, Pfizer Inc, Veridex LLC; Stock Ownership: Oncimmune Ltd.

    Ian E Krop, MD, PhD
    Associate Physician
    Dana-Farber Cancer Institute
    Assistant Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreement: Novartis Pharmaceuticals Corporation; Investigator on Trial: Genentech BioOncology.

    Hannah M Linden, MD
    Associate Professor of Medicine
    University of Washington
    Harborview Medical Center
    Seattle Cancer Care Alliance
    Seattle, Washington

    Paid Research: Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Pfizer Inc.

    Eleftherios P Mamounas, MD, MPH
    Professor of Surgery
    Northeastern Ohio Universities
    College of Medicine
    Medical Director, Aultman Cancer Center
    Canton, Ohio

    Advisory Committee: Genomic Health Inc, Novartis Pharmaceuticals Corporation; Consulting Agreement: Genomic Health Inc; Speakers Bureau: Celgene Corporation, Genomic Health Inc.

    Kathy D Miller, MD
    Sheila D Ward Scholar of Medicine
    Associate Professor of Medicine
    The Indiana University Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana

    Advisory Committee: Clovis Oncology, Genentech BioOncology; Clinical Trials: Geron, Merrimack Pharmaceuticals; Consulting Agreements: Bristol-Myers Squibb Company, Roche Laboratories Inc; Paid Research: Clovis Oncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company; Speakers Bureau: Genentech BioOncology, Roche Laboratories Inc.

    Charles L Vogel, MD
    Professor of Medicine
    University of Miami Miller School of Medicine
    Sylvester Comprehensive Cancer Center at Deerfield Beach
    Deerfield Beach, Florida

    Advisory Committee: Amgen Inc, Aveo Pharmaceuticals, Genentech BioOncology, Roche Laboratories Inc; Speakers Bureau: Amgen Inc, GlaxoSmithKline.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Pharmaceuticals.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Abbott Laboratories, Celgene Corporation, Eisai Inc, Genentech BioOncology, Genomic Health Inc and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: May 2012
    Expiration date: May 2013

Acknowledge and close

Watch video
(WIFI is recommended for best performance):